Dataset Information

Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial.

ABSTRACT:

Background

Current guidelines for lung cancer screening increased a positive scan threshold to a 6 mm longest diameter. We extracted radiomic features from baseline and follow-up screens and performed size-specific analyses to predict lung cancer incidence using three nodule size classes (<6 mm [small], 6-16 mm [intermediate], and ?16 mm [large]).

Methods

We extracted 219 features from baseline (T0) nodules and 219 delta features which are the change from T0 to first follow-up (T1). Nodules were identified for 160 incidence cases diagnosed with lung cancer at T1 or second follow-up screen (T2) and for 307 nodule-positive controls that had three consecutive positive screens not diagnosed as lung cancer. The cases and controls were split into training and test cohorts; classifier models were used to identify the most predictive features.

Results

The final models revealed modest improvements for baseline and delta features when compared to only baseline features. The AUROCs for small- and intermediate-sized nodules were 0.83 (95% CI 0.76-0.90) and 0.76 (95% CI 0.71-0.81) for baseline-only radiomic features, respectively, and 0.84 (95% CI 0.77-0.90) and 0.84 (95% CI 0.80-0.88) for baseline and delta features, respectively. When intermediate and large nodules were combined, the AUROC for baseline-only features was 0.80 (95% CI 0.76-0.84) compared with 0.86 (95% CI 0.83-0.89) for baseline and delta features.

Conclusions

We found modest improvements in predicting lung cancer incidence by combining baseline and delta radiomics. Radiomics could be used to improve current size-based screening guidelines.

SUBMITTER: Cherezov D

PROVIDER: S-EPMC6308046 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial.

Cherezov Dmitry D Hawkins Samuel H SH Goldgof Dmitry B DB Hall Lawrence O LO Liu Ying Y Li Qian Q Balagurunathan Yoganand Y Gillies Robert J RJ Schabath Matthew B MB

Cancer medicine 20181201 12

<h4>Background</h4>Current guidelines for lung cancer screening increased a positive scan threshold to a 6 mm longest diameter. We extracted radiomic features from baseline and follow-up screens and performed size-specific analyses to predict lung cancer incidence using three nodule size classes (<6 mm [small], 6-16 mm [intermediate], and ≥16 mm [large]).<h4>Methods</h4>We extracted 219 features from baseline (T0) nodules and 219 delta features which are the change from T0 to first follow-up (T1 ...[more]

PMID: 30507033

Similar Datasets

Project description:Background: The aim of the study was to evaluate the role of different immunohistochemical and radiomics features in patients with small cell lung cancer (SCLC). Methods: Consecutive patients with histologically proven SCLC with limited (n = 47, 48%) or extensive disease (n = 51, 52%) treated with radiotherapy and chemotherapy at our department were included in the analysis. The expression of different immunohistochemical markers from the initial tissue biopsy, such as CD56, CD44, chromogranin A, synaptophysin, TTF-1, GLUT-1, Hif-1 a, PD-1, and PD-L1, and MIB-1/KI-67 as well as LDH und NSE from the initial blood sample were evaluated. H-scores were additionally generated for CD44, Hif-1a, and GLUT-1. A total of 72 computer tomography (CT) radiomics texture features from a homogenous subgroup (n = 31) of patients were correlated with the immunohistochemistry, the survival (OS), and the progression-free survival (PFS). Results: The median OS, calculated from diagnosis, was 21 months for patients with limited disease and 13 months for patients with extensive disease. The expression of synaptophysin correlated with a better OS (HR 0.546 95% CI 0.308-0.966, p = 0.03). The expression of TTF-1 (HR 0.286, 95% CI: 0.117-0.698, p = 0.006) and a lower GLUT-1 H-score (median = 50, HR: 0.511, 95% CI: 0.260-1.003, p = 0.05) correlated with a better PFS. Patients without chromogranin A expression had a higher risk for developing cerebral metastases (p = 0.02) and patients with PD 1 expression were at risk for developing metastases (p = 0.02). Our radiomics analysis did not reveal a single texture feature that correlated highly with OS or PFS. Correlation coefficients ranged between -0.48 and 0.39 for OS and between -0.46 and 0.38 for PFS. Conclusions: The role of synaptophysin should be further evaluated as synaptophysin-negative patients might profit from treatment intensification. We report an, at most, moderate correlation of radiomics features with overall and progression free survival and no correlation with the expression of different immunohistochemical markers.

Project description:The National Lung Screening Trial was conducted to determine whether three annual screenings (rounds T0, T1, and T2) with low-dose helical computed tomography (CT), as compared with chest radiography, could reduce mortality from lung cancer. We present detailed findings from the first two incidence screenings (rounds T1 and T2).We evaluated the rate of adherence of the participants to the screening protocol, the results of screening and downstream diagnostic tests, features of the lung-cancer cases, and first-line treatments, and we estimated the performance characteristics of both screening methods.At the T1 and T2 rounds, positive screening results were observed in 27.9% and 16.8% of participants in the low-dose CT group and in 6.2% and 5.0% of participants in the radiography group, respectively. In the low-dose CT group, the sensitivity was 94.4%, the specificity was 72.6%, the positive predictive value was 2.4%, and the negative predictive value was 99.9% at T1; at T2, the positive predictive value increased to 5.2%. In the radiography group, the sensitivity was 59.6%, the specificity was 94.1%, the positive predictive value was 4.4%, and the negative predictive value was 99.8% at T1; both the sensitivity and the positive predictive value increased at T2. Among lung cancers of known stage, 87 (47.5%) were stage IA and 57 (31.1%) were stage III or IV in the low-dose CT group at T1; in the radiography group, 31 (23.5%) were stage IA and 78 (59.1%) were stage III or IV at T1. These differences in stage distribution between groups persisted at T2.Low-dose CT was more sensitive in detecting early-stage lung cancers, but its measured positive predictive value was lower than that of radiography. As compared with radiography, the two annual incidence screenings with low-dose CT resulted in a decrease in the number of advanced-stage cancers diagnosed and an increase in the number of early-stage lung cancers diagnosed. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.).

Dataset Information

Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial.

Background

Methods

Results

Conclusions

Publications

Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets